TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TANDEM DIABETES CARE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.38+0.14 (+0.86%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- –
- Dividend yield
- –
TANDEM DIABETES CARE INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supplies and other | $139.91M | $136.80M | $150.32M | $139.14M | $128.81M | $132.30M | $128.24M | $128.13M | $113.88M | $105.53M | $117.91M | $105.82M | 55.0% | +8.6% |
| Pump | $114.65M | $110.40M | $140.06M | $110.11M | $111.87M | $102.10M | $124.21M | $114.80M | $107.88M | $87.29M | $91.43M | $88.04M | 45.0% | +2.5% |
| Net sales recognized (deferred) for Tandem Choice program | – | – | $0 | $0 | $0 | $0 | $30.20M | $1.04M | $154.00K | -$1.15M | – | -$8.24M | – | – |
| Deferral for Tandem Choice program | – | – | – | – | – | – | – | – | – | -$1.15M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $179.29M | $160.84M | $210.46M | $175.63M | $170.21M | $150.63M | $214.56M | $171.65M | $156.71M | $129.76M | $150.91M | $130.22M | 70.4% | +5.3% |
| International | $75.27M | $86.38M | $79.92M | $73.62M | $70.47M | $83.79M | $68.09M | $72.32M | $65.20M | $61.91M | $45.88M | $55.40M | 29.6% | +6.8% |
From the segment and revenue-disaggregation notes of Tandem Diabetes Care's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.